ORG Wealth Partners LLC Sells 1,568 Shares of Fresenius Medical Care AG (NYSE:FMS)

ORG Wealth Partners LLC trimmed its position in Fresenius Medical Care AG (NYSE:FMSFree Report) by 29.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,683 shares of the company’s stock after selling 1,568 shares during the period. ORG Wealth Partners LLC’s holdings in Fresenius Medical Care were worth $83,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wulff Hansen & CO. lifted its holdings in Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after buying an additional 325,439 shares during the period. Moran Wealth Management LLC lifted its stake in shares of Fresenius Medical Care by 47.0% in the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the period. Quantinno Capital Management LP boosted its position in shares of Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in shares of Fresenius Medical Care by 60.4% during the third quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock worth $1,340,000 after purchasing an additional 23,692 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fresenius Medical Care in the third quarter valued at about $420,000. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Performance

Shares of FMS stock opened at $22.50 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $24.31. The company’s 50 day moving average price is $22.50 and its two-hundred day moving average price is $20.76. The company has a market capitalization of $13.20 billion, a P/E ratio of 18.60, a price-to-earnings-growth ratio of 0.95 and a beta of 0.92.

Analysts Set New Price Targets

A number of brokerages have issued reports on FMS. Berenberg Bank started coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price on the stock. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research note on Friday, January 3rd. They issued a “strong-buy” rating for the company. Truist Financial boosted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.

Read Our Latest Stock Analysis on Fresenius Medical Care

Fresenius Medical Care Company Profile

(Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Recommended Stories

Institutional Ownership by Quarter for Fresenius Medical Care (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.